A Proposal for Creating a Guideline for Cancer Registration of the Fibromatosis, PEComa Group, Malignant Lymphoma In Situ and Dendritic Cell Tumors (III).
- Author:
Changyoung YOO
1
;
Chang Suk KANG
;
Yoon La CHOI
;
Hye Yoon KANG
;
Jin Man KIM
;
Young Hye KOH
;
Joo Hee LEE
;
Seung Sook LEE
;
In Sun KIM
;
Dong Hoon KIM
;
Yong Ku PARK
;
Jin Hee SOHN
Author Information
1. Department of Pathology, St. Vincent's Hospital, The Catholic University of Korea College of Medicine, Suwon, Korea.
- Publication Type:Original Article
- Keywords:
ICD-O3;
Behavior code;
Hematologic malignancy;
Soft tissue neoplasms
- MeSH:
Dendritic Cells;
Epithelioid Cells;
Fibroma;
Hematologic Neoplasms;
Lymphoma;
Lymphoma, Follicular;
Perivascular Epithelioid Cell Neoplasms;
Surveys and Questionnaires;
Rare Diseases;
Soft Tissue Neoplasms
- From:Korean Journal of Pathology
2012;46(5):436-442
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Understanding the biologic behavior of a tumor is a prerequisite for tumor registration code assignment. The aim of this report was to propose appropriate behavior codes of the International Classification of Disease Oncology 3 (ICD-O3) to rare, yet pathologically interesting hematopoietic and soft tissue tumors. METHODS: The Study Group for Hematopathology, the Bone and Soft Tissue Pathology Study Group, and the Cancer Registration Committee prepared the questionnaire containing provisional behavior codes of selected diseases. RESULTS: In situ lesions of mantle cell and follicular lymphomas, dendritic cell tumors, and neoplasms with perivascular epithelioid cell differentiation (PEComa), not otherwise specified were classified as malignant (-/3). The fibromatosis group, with the exception of lipofibromatosis, was proposed as benign (-/0). Lipofibromatosis and several diseases that belong to the PEComa group were proposed as uncertain malignant potential (-/1). For the hematologic and soft tissue tumors, 274 and 288 members of the Korean Society of Pathologists, respectively, provided opinions through questionnaire, and most responders showed agreement with the provisional behavior code proposed. CONCLUSIONS: The determination of behavior codes for the rare diseases described in this study, especially those of the PEComa group or malignant lymphoma, could be viewed as impractical and premature, but this study provides the basis for future research on this topic.
